Completed PHASE3 INTERVENTIONAL NCT00046904

Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer

Phase III Placebo-Controlled, Randomized, Double-Blind Comparison Of Etanercept (Enbrel) Versus Placebo For The Treatment Of Cancer-Associated Weight Loss And Anorexia

Sponsor: Mayo Clinic

Conditions Anorexia Cachexia Unspecified Adult Solid Tumor, Protocol Specific

Interventions etanercept

Updated 6 times since 2017 Last updated: May 4, 2011 Started: May 31, 2003 Primary completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00046904, this PHASE3 trial focuses on Anorexia and Cachexia and remains completed. Sponsored by Mayo Clinic, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic
National Cancer Institute (NCI)

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Bismarck, United States , Cedar Rapids, United States , Danville, United States , Des Moines, United States , Honolulu, United States , Jacksonville, United States , Mobile, United States , Omaha, United States , Peoria, United States and 9 more locations